Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended June 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	13,063			$	—			$	—			$	13,063
Grant and other revenue			247,983				—				—				247,983
Total revenue			261,046				—				—				261,046
Research and development expenses			1,358,123				139,933				—				1,498,056
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				873				1,411,879				1,412,752
Depreciation and amortization ⁽²⁾			6,041				—				13,817				19,858
Loss from operations ⁽³⁾			(1,103,118	)			(140,806	)			(1,425,696	)			(2,669,620	)
Other expense ⁽⁴⁾			—				—				(4,420	)			(4,420	)
Net loss			(1,103,118	)			(140,806	)			(1,430,116	)			(2,674,040	)
Total assets, net of depreciation and amortization:
United States		$	269,464			$	—			$	10,811,515			$	11,080,979
International			199,741				—				590				200,331
Capital expenditures			—				—				2,707				2,707

Three Months Ended June 30, 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	8,920			$	—			$	—			$	8,920
Grant and other revenue			215,458				46,723				—				262,181
Total revenue			224,378				46,723				—				271,101
Cost of revenue			357				—				—				357
Research and development expenses			1,193,151				88,628				—				1,281,779
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				972				1,309,363				1,310,335
Depreciation and amortization ⁽²⁾			—				—				19,256				19,256
Loss from operations ⁽³⁾			(969,130	)			(42,877	)			(1,328,619	)			(2,340,626	)
Other income ⁽⁴⁾			—				—				15,007				15,007
Net loss			(969,130	)			(42,877	)			(1,313,612	)			(2,325,619	)
Total assets, net of depreciation and amortization:
United States		$	107,185			$	36,483			$	6,463,015			$	6,606,683
Capital expenditures			—				—				1,947				1,947

Six Months Ended June 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	35,549			$	—			$	—			$	35,549
Grant and other revenue			349,234				—				—				349,234
Total revenue			384,783				—				—				384,783
Research and development expenses			2,452,513				268,297				—				2,720,810
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				2,879				3,622,870				3,625,749
Depreciation and amortization ⁽²⁾			12,081				—				25,525				37,606
Loss from operations ⁽³⁾			(2,079,811	)			(271,176	)			(3,648,395	)			(5,999,382	)
Other income ⁽⁴⁾			—				—				358,450				358,450
Net loss			(2,079,811	)			(271,176	)			(3,289,945	)			(5,640,932	)
Total assets, net of depreciation and amortization:
United States		$	269,464			$	—			$	10,811,515			$	11,080,979
International			199,741				—				590				200,331
Capital expenditures			—				—				2,707				2,707

Six Months Ended June 30, 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	24,141			$	—			$	—			$	24,141
Grant and other revenue			274,374				128,858				—				403,232
Total revenue			298,515				128,858				—				427,373
Cost of revenue			966				—				—				966
Research and development expenses			2,150,777				130,271				—				2,281,048
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				(550	)			3,121,796				3,121,246
Depreciation and amortization ⁽²⁾			—				—				36,099				36,099
Loss from operations ⁽³⁾			(1,853,228	)			(863	)			(3,157,895	)			(5,011,986	)
Other income ⁽⁴⁾			—				—				12,759				12,759
Net loss			(1,853,228	)			(863	)			(3,145,136	)			(4,999,227	)
Total assets, net of depreciation and amortization:
United States		$	107,185			$	36,483			$	6,463,015			$	6,606,683
Capital expenditures			—				—				8,406				8,406